IMVT (Immunovant) Additional Paid-In Capital: $2,633.00 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMVT Immunovant Inc IMVT
29 GF Score
Price $39.25
! 2 Warning Signs
View Full Analysis

What is Immunovant Additional Paid-In Capital?

Immunovant IMVT +0.36% 29 Additional Paid-In Capital is $2,633.00 Mil as of Jun. 2026. GuruFocus rates IMVT with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.


Immunovant's quarterly additional paid-in capital increased from Dec. 2025 ($2,582.19 Mil) to Mar. 2026 ($2,596.97 Mil) and increased from Mar. 2026 ($2,596.97 Mil) to Jun. 2026 ($2,633.00 Mil).

Immunovant's annual additional paid-in capital increased from Mar. 2024 ($1,441.52 Mil) to Mar. 2025 ($1,945.50 Mil) and increased from Mar. 2025 ($1,945.50 Mil) to Mar. 2026 ($2,596.97 Mil).

Immunovant Additional Paid-In Capital Related Terms

Immunovant Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Immunovant's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunovant Additional Paid-In Capital Chart

Immunovant Annual Data
Trend Dec18 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Additional Paid-In Capital
Get a 7-Day Free Trial 824.80 927.98 1,441.52 1,945.50 2,596.97

Immunovant Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,966.92 2,004.88 2,582.19 2,596.97 2,633.00
IMVT
29GF Score
Immunovant Inc IMVT
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunovant Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $2,633.00 Mil mean?
Immunovant (IMVT) has a Additional Paid-In Capital of $2,633.00 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Immunovant and its competitors.
Is Immunovant's Additional Paid-In Capital too high?
Immunovant's current Additional Paid-In Capital is $2,633.00 Mil. Overall, Immunovant has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Immunovant's Additional Paid-In Capital compare to IBRX and TGTX?
Immunovant's Additional Paid-In Capital of $2,633.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Immunovant and its competitors. Immunovant's current Additional Paid-In Capital is $2,633.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovant stock overvalued right now?
Immunovant (IMVT) has a current Additional Paid-In Capital of $2,633.00 Mil. The current Additional Paid-In Capital is $2,633.00 Mil. Immunovant's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Immunovant (IMVT), the current Additional Paid-In Capital is $2,633.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immunovant Business Description

Address 1000 Park Forty Plaza, New York, NC, USA, 27713
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
29GF Score

Get the complete analysis for IMVT

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$39.25
Price